BY ALBERT RONNING-ANDERSSON
-
Lundbeck Foundation grants DKK 222m donation to Danish neuroscience research
With a give of DKK 222m from the Lundbeck Structure, Neuroscience Academy Denmark has the ability to fund the startup of 48 extra PhD scholarships in the years 2026-2028.
-
Leo Pharma changes CEO in the US
The business’s present magnate in the United States has actually surrendered and taken one more task in “a big pharmaceutical business”.
-
Lundbeck reports positive results from epilepsy drug study
Lundbeck approximates that the epilepsy prospect bexicaserin can possibly get to peak sales of USD 1.5-2bn.
-
Biogen’s ailing partner rejects takeover bid – will look at other options
The board of Sage Rehab has actually all declined Biogen’s USD 469m procurement proposal. The troubling Biogen companion will certainly rather begin a procedure of “tac…
-
Novo Nordisk Pharmatech expands collaboration with US partner
The workout belongs to an approach to settle Novo Nordisk Pharmatech’s companion landscape.
-
Crucial quarter for Genmab: J&J must decide on “miracle drug”
Genmab chief executive officer Jan van de Winkel claims there are various other alternatives if the bargain fails.
-
Former GN finance chief returns to hearing industry in new CFO role
The chance to return right into the listening device market and a main setting in the market’s worth chain drew in Morten P. Toft to the Novo Holdings-owned business, Sonion.
-
Zealand Pharma CEO on partner hunting: “We are exactly where we want to be”
Talks with prospective companions for Zealand Pharma’s prospective crown gem in weight problems, petrelintide, get on track, according to chief executive officer.
-
EU moves closer to electronic leaflets for drug packages
Changing to digital plan brochures is anticipated to bring ecological and financial advantages to the pharmaceutical market.
-
Evaxion has all patients lined up for Phase 2 trial with lead candidate
The routine is thus on course, and information is anticipated to remain to get here in the 2nd fifty percent of 2025.